We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00128830
First Posted: August 10, 2005
Last Update Posted: June 20, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
Results First Submitted: February 27, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Human Immunodeficiency Virus Type 1
Interventions: Drug: Etravirine (ETR)
Drug: Nucleotide reverse transcriptase inhibitors (NRTIs)
Drug: Protease inhibitors (PIs)
Drug: Enfuvirtide (ENF)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
In this study, 211 participants were enrolled in 12 different countries. The majority of participants (49%) were enrolled in the United States.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
In total, 211 participants (93 who rolled over from the etravirine arm of study TMC125-C203 (NCT00412646), 85 who rolled over from the etravirine arm of study TMC125-C223 (NCT00081978), 29 who rolled over from study TMC125-C211 (NCT00111280) and 4 who rolled over from study TMC125-C209) received treatment with etravirine.

Reporting Groups
  Description
Etravirine 800 mg twice daily (formulation TF035), and after formulation switch, 200 mg twice daily (formulation F060)

Participant Flow:   Overall Study
    Etravirine
STARTED   211 
COMPLETED   139 
NOT COMPLETED   72 
Adverse Event                10 
Withdrawal by Subject                14 
Lost to Follow-up                4 
Reached a virologic endpoint                29 
Non-compliant                4 
Discontinued or ineligible for study                2 
Other                9 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Etravirine 800 mg twice daily (formulation TF035), and after formulation switch, 200 mg twice daily (formulation F060)

Baseline Measures
   Etravirine 
Overall Participants Analyzed 
[Units: Participants]
 211 
Age 
[Units: Years]
Median (Full Range)
 46.0 
 (32 to 70) 
Gender 
[Units: Participants]
 
Female   21 
Male   190 
Race/Ethnicity, Customized 
[Units: Participants]
 
Asian   1 
Black or African American   24 
White   164 
Hispanic   16 
Other   6 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Adverse Events   [ Time Frame: Up to 3 years ]

2.  Secondary:   Number of Participants Who Achieved Virologic Response (ie, Viral Load Less Than 50 Copies/mL) at Week 48   [ Time Frame: Week 48 ]

3.  Secondary:   Number of Participants Who Achieved Virologic Response (ie, Viral Load Less Than 50 Copies/mL) at Week 96   [ Time Frame: Week 96 ]

4.  Secondary:   Number of Participants Who Achieved Virologic Response (ie, Viral Load Less Than 50 Copies/mL; Less Than 400 Copies/mL; and Greater Than or Equal to 1 Log 10 Decrease From Baseline) at Week 96   [ Time Frame: Week 96 ]

5.  Secondary:   Number of Participants Who Achieved Virologic Response (ie, Viral Load Less Than 50 Copies/mL; Viral Load Less Than 400 Copies/mL; and Greater Than or Equal to 1 log10 Decrease From Baseline) at Week 192   [ Time Frame: Week 192 ]

6.  Secondary:   Median Change From TMC125-C229 Basline in Cluster of Differentiation 4 (CD4+) Cell Count at Week 48   [ Time Frame: Week 48 ]

7.  Secondary:   Median Change From TMC125-C229 Baseline in Cluster of Differentiation 4 (CD4+) Cell Count at Week 96   [ Time Frame: Week 96 ]

8.  Secondary:   Median Change in Cluster of Differentiation 4 (CD4+) Cell Count From Baseline in TMC125-C229 Feeder Study at Week 96   [ Time Frame: Week 96 ]

9.  Secondary:   Median Change in Cluster of Differentiation 4 (CD4+) Cell Count From Baseline in TMC125-C229 Feeder Study at Week 192   [ Time Frame: Week 192 ]

10.  Secondary:   Number of Participants With Emerging Mutation (Reverse Transcriptase Mutation)   [ Time Frame: Baseline and Endpoint (ie, the last available time point during the treatment period) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Trial Physician
Organization: Tibotec Pharmaceuticals
phone: +32-14-607-767



Responsible Party: Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier: NCT00128830     History of Changes
Obsolete Identifiers: NCT00980772
Other Study ID Numbers: CR002731
TMC125-C229 ( Other Identifier: Tibotec Pharmaceuticals, Ireland )
First Submitted: August 8, 2005
First Posted: August 10, 2005
Results First Submitted: February 27, 2013
Results First Posted: April 9, 2013
Last Update Posted: June 20, 2013